Fractyl Health Appoints Lara Smith Weber as New CFO to Drive Commercial-Stage Preparedness

summarizeSummary

Fractyl Health announced the appointment of Lara Smith Weber as its new Chief Financial Officer, effective January 12, 2026, replacing Lisa Davidson who resigned amicably after 10 years with the company.

check_boxKey Events

• New Chief Financial Officer Appointed

  Lara Smith Weber has been appointed as the new Chief Financial Officer, effective January 12, 2026. She will oversee finance, accounting, and investor relations.

• Outgoing CFO Resignation

  Lisa Davidson resigned from her role as Chief Financial Officer, effective December 31, 2025, after 10 years with the company. Her resignation was not due to any disagreement.

• New CFO Compensation Package

  Ms. Smith Weber will receive a $150,000 signing bonus, an annual base salary of $492,100, a target annual bonus of 40% of her base salary, and an option to purchase 1,036,800 shares of common stock with a 4-year vesting period.

• Outgoing CFO Severance and Consulting

  Ms. Davidson will receive $630,000 in cash payments, up to 18 months of COBRA continuation, full vesting of outstanding time-based equity awards, an extended 12-month exercise period for vested options, and will provide consulting services for up to three months at $400 per hour.

auto_awesomeAnalysis

Fractyl Health's appointment of Lara Smith Weber as Chief Financial Officer is a very important development, signaling the company's strategic focus on transitioning to commercial-stage operations. Ms. Smith Weber's extensive experience in building financial organizations and guiding companies through operational scaling, as highlighted in the filing, directly aligns with Fractyl's stated 'pivotal moment.' The compensation package for the new CFO, particularly the grant of options for 1,036,800 shares, represents a significant equity incentive. The amicable departure of long-serving CFO Lisa Davidson, coupled with a substantial severance package including full vesting of time-based equity and a consulting agreement, ensures a smooth leadership transition. This change is positioned to strengthen the company's financial and operational discipline as it advances its clinical programs and prepares for commercialization.